Depomed — Proxy Contest (September 2015)
35 slides from Depomed's proxy contest presentation, Sep 15, 2015
Slide 1: Transformation Complete: A Specialty Pharmaceutical Leader Focused in Pain and Neurology
Transformation Complete: A Specialty Pharmaceutical Leader Focused in Pain and Neurology September 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements The statements that are not historical facts contained in this presentation are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to Depomed’s acquisition of the NUCYNTA® franchise in the United States, Depomed’s p
Slide 3: Important Additional Information
Important Additional Information Important Additional Information This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. Depomed has filed a solicitation/recommendation statement on Schedule 14D-9 with the U.S. Securities and Exchange Commission (t
Slide 4: Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth
4 September 2015 Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth Strong Product Portfolio Marketing six branded, differentiated products in pain and neurology with lengthy exclusivity1 Track Record of Accelerated Growth Organic growth - success increasing product sales, Rx
Slide 5: Depomed's Track Record of Successful Deals Builds Value
Reworked Santarus deal and tripled net revenue 47% revenue growth Q2 2015 over Q2 2014 Acquired Dec 2013; relaunched Q1 2014; 35% increase in demand Q2 2015 over Q2 2014 Q3 2011 Q4 2011 Q4 2013 TYPE 2 DIABETES DEAL Non-strategic milestones & royalties sold for $240 million Q4 2013 Relaunch Q4 2013 f
Slide 6: Depomed's "Acquire, Integrate, Grow" Business Model
Depomed’s “Acquire, Integrate, Grow” Business Model Driving An Accelerated Growth Cycle 6 September 2015 ACQUIRE Pain and neurology products with lengthy exclusivity and peak sales ahead INTEGRATE Speed and efficiency from playbook based on past success with same team GROW Repositioning and marketin
Slide 7: Execution of Business Model Driving Triple Digit Growth in Sales and Profitability
Depomed’s Execution of Business Model Driving Triple Digit Growth in Sales and Significant Profitability 7 $500K $27.1M $58.1M $114M $320M-340M September 2015 2015 Total Product Sales Guidance (Includes NUCYNTA starting April 2, 2015) Adjusted EBITDA (Midpoint of adjusted EBITDA Guidance) $102.5M At
Slide 8: Execution of Business Model Driving Sales Growth, Rx Growth, Market Share
Depomed - Execution of Business Model Driving Sales Growth, Rx Growth, Market Share September 2015 Product Sales Growth (Y/Y) Prescription Growth (Y/Y) Market Share Growth (Q/Q) 38% growth 2Q15: $20.9M 18% growth 2Q15: 83k 2Q15: 3.2% share 2Q14: 2.8% share 36% growth 2Q15: $6.8M 35% growth 2Q15: 35k
Slide 9: Depomed's Demonstrated Track Record of Value Creation
Depomed’s Demonstrated Track Record of Value Creation 9 September 2015 Depomed is in a Period of Significant Growth and is Well-Positioned for Future Success Covering 8/31/10 to 8/31/15 Source: Stock chart from BigCharts.com 1-Year 2-Year 3-Year 5-Year 75% 276% 409% 650% Total Shareholder Return to
Slide 10: Depomed 2Q 2015 - Continued Strong Performance With Record Sales and Cash Flow
Depomed 2Q 2015 - Continued Strong Performance With Record Sales and Cash Flow - Revenue Up 234% Over Prior Year 10 September 2015 Record Quarterly Results 2015 Guidance Updated* Additional Highlights Net product sales of $94.3M (234% over Q2 2014) Added $55M of cash in second quarter Product sales
Slide 11: Depomed Expected to Be a Top 5 Branded Pain Company by 2016
11 11 September 2015 Acute Pain Breakthrough Cancer Pain Chronic Pain Neuropathic Pain Migraine ü ü ü ü ü ü ü ü ü ü ü ü ü ü Source: Depomed Marketing, company websites Depomed Expected to be a Top 5 Branded Pain Company by 2016 ü We Believe Depomed is Building the Most Complete Pain Portfolio in the
Slide 12: NUCYNTA Leading The Latest Chapter of Depomed's Growth Story
NUCYNTA Leading The Latest Chapter of Depomed’s Growth Story Adds significant revenue and earnings to an already strong business Only new chemical entity in CII space approved by FDA in last 30 years Competes in multi-billion dollar pain market Exclusivity expected for a decade or more Significant o
Slide 13: NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion in Sales
Depomed’s NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion in Sales 13 September 2015 Proper Dosing Pricing and Access Positioning Promotion Significantly increased promotion and marketing efforts Revamped product positioning and messaging Maximize brand through pricing and access strategie
Slide 14: Promotion: Significantly Increased to Drive Prescriptions and Market Share
Promotion: Significantly Increased to Drive Prescriptions and Market Share 14 September 2015 Increased Sales Force 1 Optimized Medical Education Identifying Appropriate Target Prescribers Promotion strategy consists of: 3-fold increase to 275 reps Highly experienced in pain and neurology Resumed ful
Slide 15: Promotion Progress: Accelerating Demand - Rx Growth of 15.5%
Sales force delivering approximately 10k NUCYNTA calls per week since re-launch PAINWeek® 2015 1,000+ attendees at NUCYNTA and CME-sponsored symposia Speaker Program Education: early focus and success 710 attendees on 7/30 national webcast; >200 high decile targets 650+ programs targeted for 2015 Ye
Slide 16: Positioning: Only FDA Approved Product Addressing Both Nociceptive and Neuropathic Pain
Positioning: Only FDA Approved Product that Addresses Both Nociceptive and Neuropathic Pain 16 September 2015 Chronic pain affects 1/3 of the US population More than 100 million adults with chronic pain 31 million with chronic lower back pain (CLBP) Potential significant impact from even modest upti
Slide 17: Positioning Progress: Market Share Increased From 1.46% to 1.63%
Competes in >$5 billion dollar Long Acting Opioid (LAO) market Increased promotional activities with new messaging resonating with prescribers Key opinion leaders educating on potential dual mechanism and titration Market share of LAO market up .17% in just twelve weeks 17 September 2015 Positioning
Slide 18: Pricing and Access: Maximizing Brand Through Pricing and Access Strategies
Pricing and Access: Maximizing Brand Through Pricing and Access Strategies 18 September 2015 94% of commercial lives have access to NUCYNTA and NUCYNTA ER United Healthcare Commercial moved NUCYNTA ER in front of Oxycontin on formulary as of July 1, 2015 Oxycontin removed from Tier 2 and now require
Slide 19: Proper Dosing: Education on Titration is Key
Proper Dosing: Education on Titration is Key Average dose in low back pain trials was ~400mg/day after titration 19 September 2015 4 200 mg Proper Dose May Improve Physician and Patient Experience as well as Increase Average Selling Price Expert Opin. Pharmacother. (2010) 11(11):1787-1804 250 mg ~40
Slide 20: NUCYNTA Patent Protection Expected to Provide Market Exclusivity for a Decade or More
NUCYNTA Patent Protection Expected to Provide Market Exclusivity for a Decade or More 20 September 2015 NUCYNTA >$500MM by 2020 and $1 Billion Expected Before Patent Expiry February 2023: Expiry of patents covering tapentadol (composition of matter plus pediatric extension) December 2025: Expiry of
Slide 21: Highly Differentiated Growing Portfolio of Assets in Addition to NUCYNTA
21 September 2015 Depomed’s Highly Differentiated Growing Portfolio of Assets in Addition to NUCYNTA Product Differentiation 2Q Annualized Revenues Growth Over 1Q 2015 Expected Exclusivity 1x daily with less dizziness and somnolence $84M 21% April 2015 ANDA settlement provides exclusivity to 2024 On
Slide 22: Depomed Sales Force Effectively Targets Key Specialties
Depomed Sales Force Effectively Targets Key Specialties Core Sales Force n=275 Cancer Pain Specialists n=24 Pain Focused Neurology Focused 22 September 2015
Slide 23: Ability to Efficiently Execute and Deliver Growth - Gralise
23 September 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - Gralise Reacquired marketing rights March 2011 and received $40M payment Launched in October 2011 >$84 million run rate as of Q2 2015 Tier 2 coverage at the three largest pharmacy benefit managers, CVS/Caremark, ESI, Cat
Slide 24: Ability to Efficiently Execute and Deliver Growth - CAMBIA
24 September 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - CAMBIA Acquired in December 2013 for $48.7M Relaunched in December 2013 $27 million run rate as of Q2 2015 Only single agent in its therapeutic class approved in the U.S. for treatment of acute migraine attacks in adults
Slide 25: Ability to Efficiently Execute and Deliver Growth - Lazanda
25 September 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - Lazanda Acquired in July 2013 for $4M Relaunched in August 2013 $15.4 million run rate as of Q2 2015 Market share has doubled in last 12 months and 4x since relaunch Effective January 1st, only branded rapid acting fenta
Slide 26: Lengthy Exclusivity Periods Mean Products Contributing to Revenue Growth
Lengthy Exclusivity Periods Mean Products Contributing to Revenue Growth for a Long Time 26 September 2015 Securing Market Exclusivity for Depomed Products Well Into Next Decade Product Expected Exclusivity 2028 Acquired April 2015; composition of matter patent to 2022/2023; polymorph and method of
Slide 27: Acquire, Integrate, and Grow Strategy Will Continue to Create Value
27 September 2015 We Expect Depomed’s Acquire, Integrate, and Grow Strategy will Continue to Create Value Maintain pain and neurology focus, leveraging management’s expertise Products with current annual revenue between $20-$200MM+ Targeting products with lengthy exclusivity and future peak sales Ra
Slide 28: Collaborations and Intellectual Property Provide Revenue Upside Over the Next Decade
Depomed’s Collaborations and Intellectual Property Provide Revenue Upside Over the Next Decade 28 IP Litigation Potential future cash flow from IP litigation against Purdue Pharma and Endo PTAB has confirmed the patentability of each of the 25 claims subject to Purdue IPRs; Endo decision expected by
Slide 29: Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth
29 September 2015 Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth Strong Product Portfolio Marketing six branded, differentiated products in pain and neurology with lengthy exclusivity Track Record of Accelerated Growth Organic growth - success increasing product sales, Rx
Slide 30: Depomed: Current Status Related to Hostile Offer
Depomed: Current Status Related to Hostile Offer 30 September 2015 “Our Board of Directors unanimously concluded that Horizon’s unsolicited exchange offer significantly undervalues Depomed, is inadequate and is not in the best interests of Depomed and its shareholders. We remain very confident in th
Slide 31: Percentage Ownership Offered Well Below Equity Contribution
Percentage Ownership Offered Well Below Equity Contribution Based on Research Median Estimates 31 September 2015 Based on PF Equity Contribution (1) (2) (3) (4) (5) (6) Notes Equity ownership based on exchange ratio of 0.95 of an ordinary share of Horizon per Depomed share and Horizon current price
Slide 32: Depomed's Directors are Industry Experienced
Depomed’s Directors are Industry Experienced Peter D. Staple (chair) CEO, Corium International, Inc. Vicente Anido, Jr. CEO, Aerie Pharmaceuticals, Inc. Karen A. Dawes President, Knowledgeable Decisions Louis J. Lavigne, Jr. Former CFO, Genentech, Inc. Samuel R. Saks, MD Co-Founder, Co-CEO, Jazz Pha
Slide 33: Depomed Has Retained Independent and Experienced Advisors
Depomed has Retained Independent and Experienced Advisors in Connection with Evaluation of Hostile Proposal Financial Advisors: Morgan Stanley & Co. LLC Leerink Partners LLC Each firm has performed substantial and customary financial analysis and separately advised Board that hostile proposal does n
Slide 34: Board Action Intended to Provide Time to Consider Hostile Proposal
Board Action Intended to Provide Depomed Board and Shareholders Time to Consider Hostile Proposal Shareholders Rights Plan: Limited duration (expires at the next annual meeting) Gives Depomed Board time to fully assess and respond to any proposals Not intended to prevent an acquisition of Depomed on
Slide 35: Thank You
pve KS < Depomed Thank You www.depomed.com